Indications
Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
Composition
- Active substance
- ocriplasmin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Jetrea
- Active substance
- ocriplasmin
- ATC code
- S01XA22
- Group
- Sensory organs
- Therapeutic area
- Retinal Diseases
- Marketing authorisation holder
- Inceptua AB
- Status
- Withdrawn
- EU authorisation
- 13 Mar 2013
- Withdrawn